Resumen
Las enfermedades pulmonares intersticiales difusas (EPID) están formadas por un conjunto heterogéneo de entidades de diferentes etiologías. Entre ellas, uno de los grupos más importantes por gravedad y frecuencia son las EPID secundarias a enfermedades autoinmunes sistémicas. Las enfermedades del tejido conectivo (ETC) o conectivopatías son un grupo de patologías de base autoinmune con repercusión sistémica. La EPID aparece con una frecuencia variable en cada una de ellas, aunque cuando lo hace suele tener importantes implicaciones en la gravedad del cuadro y en el pronóstico. En esta actualización trataremos de explicar los diferentes tipos de EPID, en sus formas inflamatorias y de predominio fibrótico, que surgen de manera secundaria a los principales tipos de ETC conocidas, así como su aproximación diagnóstica y terapéutica.
Palabras clave
Enfermedades pulmonares intersticiales difusas
Enfermedades del tejido conectivo
Autoinmune
Neumonía intersticial no específica
Neumonía intersticial usual
Abstract
Diffuse interstitial lung diseases (DILD) comprise a heterogeneous set of diseases of different etiologies. Among them, one of the most important groups for their severity and frequency are DILD secondary to systemic autoimmune diseases. Connective tissue diseases (CTD), or connectopathies, are a group of diseases with an autoimmune basis with systemic repercussions. DILD appears with a varying frequency in each of them, although when it does, it tends to have important implications on the severity of the symptoms and prognosis. In this update, we will attempt to explain the different types of DILD, in its inflammatory and predominantly fibrotic forms, that emerge secondarily to the main types of known CTD as well as their diagnostic and therapeutic approach.
Keywords
Diffuse interstitial lung diseases
Connective tissue diseases
Autoimmune
Nonspecific interstitial pneumonia
Usual interstitial pneumonia
Identifíquese
¿Aún no es suscriptor de la revista?
Comprar el acceso al artículo
Comprando el artículo el pdf del mismo podrá ser descargado
Teléfono para incidencias
De lunes a viernes de 9h a 18h (GMT+1) excepto los meses de julio y agosto que será de 9 a 15h
Llamadas desde España
932 415 960
Llamadas desde fuera de España
+34 932 415 960
Bibliografía
[1]
B. Marigliano , A. Soriano, D. Margiotta, M. Vadacca, A. Afeltra.
Lung involvement in connective tissue diseases: A comprehensive review and a focus on rheumatoid arthritis.
Autoimmun Rev., (2013), 12 pp. 1076-1084
[3]
A. Fischer , K.M. Antoniou, K.K. Brown, J. Cadranel, T.J. Corte, R.M. du Bois, et al.
An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features.
Eur Respir J., (2015), 46 pp. 976-987
[4]
American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001.
Am J Respir Crit Care Med., (2002), 165 pp. 277-304
[6]
Scleroderma lung disease.
Eur Respir Rev., (2013), 22 pp. 6-19
[7]
Diagnosis and treatment of connective tissue disease-associated interstitial lung disease.
Chest., (2013), 143 pp. 814-824
[8]
Pathologic and radiologic differences between idiopathic and collagen vascular disease-related usual interstitial pneumonia.
Chest., (2009), 136 pp. 23-30
[9]
A. Fischer , S.G. West, J.J. Swigris, K.K. Brown, R.M. du Bois.
Connective tissue disease-associated interstitial lung disease: a call for clarification.
Chest., (2010), 138 pp. 251-256
[11]
Undifferentiated connective tissue diseases (UCTD).
Autoimmun Rev., (2006), 6 pp. 1-4
[12]
B.W. Kinder , C. Shariat, H.R. Collard, L.L. Koth, P.J. Wolters, J.A. Golden, et al.
Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function.
Lung., (2010), 188 pp. 143-149
[13]
Y. Kondoh , S. Makino, T. Ogura, T. Suda, H. Tomioka, H. Amano, et al.
2020 guide for the diagnosis and treatment of interstitial lung disease associated with connective tissue disease.
Respir Investig., (2021), 59 pp. 709-740
[14]
G. Raghu , M. Remy-Jardin, J.L. Myers, L. Richeldi, C.J. Ryerson, D.J. Lederer, et al.
Diagnosis of idiopathic pulmonary fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.
Am J Respir Crit Care Med., (2018), 198 pp. e44-e68
[15]
H. Prosch , C.M. Schaefer-Prokop, E. Eisenhuber, D. Kienzl, C.J. Herold.
CT protocols in interstitial lung diseases--a survey among members of the European Society of Thoracic Imaging and a review of the literature.
Eur Radiol., (2013), 23 pp. 1553-1563
[16]
Radiología., (2012), 54 pp. 479-489
[17]
C. Mueller-Mang , C. Grosse, K. Schmid, L. Stiebellehner, A.A. Bankier.
What every radiologist should know about idiopathic interstitial pneumonias.
Radiographics., (2007), 27 pp. 595-615
[18]
The use of lung ultrasound images for the differential diagnosis of pulmonary and cardiac interstitial pathology.
J Ultrasound., (2017), 20 pp. 91-96
[19]
The lung in rheumatoid arthritis: Focus on interstitial lung disease.
Arthritis Rheumatol., (2018), 70 pp. 1544-1554
[20]
K.M. Antoniou , G.A. Margaritopoulos, N.S. Goh, K. Karagiannis, S.R. Desai, A.G. Nicholson, et al.
Combined pulmonary fibrosis and emphysema in scleroderma-related lung disease has a major confounding effect on lung physiology and screening for pulmonary hypertension.
Arthritis Rheumatol., (2016), 68 pp. 1004-1012
[21]
Management of connective tissue diseases associated interstitial lung disease: a review of the published literature.
Curr Opin Rheumatol., (2016), 28 pp. 236-245
[22]
D. Khanna , S. Mittoo, R. Aggarwal, S.M. Proudman, N. Dalbeth, E.L. Matteson, et al.
Connective tissue disease-associated interstitial lung diseases (CTD-ILD)-Report from OMERACT CTD-ILD Working Group.
J Rheumatol., (2015), 42 pp. 2168-2171
[23]
Interstitial lung disease: the diagnostic role of bronchoscopy.
J Thorac Dis., (2017), 9
[25]
Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years.
Ann Rheum Dis., (2003), 62 pp. 722-727
[28]
The value of biomarkers as predictors of outcome in patients with rheumatoid arthritis-associated usual interstitial pneumonia.
Sarcoidosis Vasc Diffuse Lung Dis., (2016), 33 pp. 216-223
[29]
C. Fernández-Díaz , S. Castañeda, R.B. Melero-González, F. Ortiz-Sanjuán, A. Juan-Mas, C. Carrasco-Cubero, et al.
Abatacept in interstitial lung disease associated with rheumatoid arthritis: national multicenter study of 263 patients.
Rheumatol Oxf Engl., (2020), 59 pp. 3906-3916
[30]
A. Manfredi , G. Cassone, F. Furini, E. Gremese, V. Venerito, F. Atzeni, et al.
Tocilizumab therapy in rheumatoid arthritis with interstitial lung disease: a multicentre retrospective study.
Intern Med J., (2020), 50 pp. 1085-1090
[32]
U.A. Walker , A. Tyndall, L. Czirják, C. Denton, D. Farge-Bancel, O. Kowal-Bielecka, et al.
Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database.
Ann Rheum Dis., (2007), 66 pp. 754-763
[33]
M. Elhai , C. Meune, M. Boubaya, J. Avouac, E. Hachulla, A. Balbir-Gurman, et al.
Mapping and predicting mortality from systemic sclerosis.
Ann Rheum Dis., (2017), 76 pp. 1897-1905
[34]
A.-M. Hoffmann-Vold , Y. Allanore, M. Alves, C. Brunborg, P. Airó, L.P. Ananieva, et al.
Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database.
Ann Rheum Dis., (2021), 80 pp. 219-227
[35]
Screening high-resolution computed tomography of the chest to detect interstitial lung disease in systemic sclerosis: A global survey of rheumatologists.
Arthritis Rheumatol., (2018), 70 pp. 971-972
[36]
A.-M. Hoffmann-Vold , T.M. Maher, E.E. Philpot, A. Ashrafzadeh, R. Barake, S. Barsotti, et al.
The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements.
Lancet Rheumatol., (2020), 2 pp. e71-e83
[37]
O. Kowal-Bielecka , J. Fransen, J. Avouac, M. Becker, A. Kulak, Y. Allanore, et al.
Update of EULAR recommendations for the treatment of systemic sclerosis.
Ann Rheum Dis., (2017), 76 pp. 1327-1339
[38]
D.P. Tashkin , M.D. Roth, P.J. Clements, D.E. Furst, D. Khanna, E.C. Kleerup, et al.
Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.
Lancet Respir Med., (2016), 4 pp. 708-719
[40]
W.W. Douglas , H.D. Tazelaar, T.E. Hartman, R.P. Hartman, P.A. Decker, D.R. Schroeder, et al.
Polymyositis-dermatomyositis-associated interstitial lung disease.
Am J Respir Crit Care Med., (2001), 164 pp. 1182-1185
[41]
Interstitial lung disease in polymyositis and dermatomyositis.
Clin Chest Med., (2019), 40 pp. 561-572
[42]
J.C. Lega , Q. Reynaud, A. Belot, N. Fabien, I. Durieu, V. Cottin.
Idiopathic inflammatory myopathies and the lung.
Eur Respir Rev., (2015), 24 pp. 216-238
[44]
Mixed connective tissue disease--an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA).
Am J Med., (1972), 52 pp. 148-159
[45]
Mixed connective tissue disease.
Best Pract Res Clin Rheumatol., (2016), 30 pp. 95-111
[46]
The risk of lymphoma development in autoimmune diseases: a meta-analysis.
Arch Intern Med., (2005), 165 pp. 2337-2344
[47]
N Engl J Med., (2020), 383 pp. 958-968
[48]
T.E. King , W.Z. Bradford, S. Castro-Bernardini, E.A. Fagan, I. Glaspole, M.K. Glassberg, et al.
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
N Engl J Med., (2014), 370 pp. 2083-2092
[49]
L. Richeldi , R.M. du Bois, G. Raghu, A. Azuma, K.K. Brown, U. Costabel, et al.
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.
N Engl J Med., (2014), 370 pp. 2071-2082
[50]
O. Distler , K.B. Highland, M. Gahlemann, A. Azuma, A. Fischer, M.D. Mayes, et al.
Nintedanib for systemic sclerosis–associated interstitial lung disease.
N Engl J Med., (2019), 380 pp. 2518-2528
[51]
K.R. Flaherty , A.U. Wells, V. Cottin, A. Devaraj, S.L.F. Walsh, Y. Inoue, et al.
Nintedanib in progressive fibrosing interstitial lung diseases.
N Engl J Med., (2019), 381 pp. 1718-1727
[52]
A.U. Wells , K.R. Flaherty, K.K. Brown, Y. Inoue, A. Devaraj, L. Richeldi, et al.
Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
Lancet Respir Med., (2020), 8 pp. 453-460
[53]
D. Khanna , C. Albera, A. Fischer, N. Khalidi, G. Raghu, L. Chung, et al.
An open-label, phase ii study of the safety and tolerability of pirfenidone in patients with scleroderma-associated interstitial lung disease: the LOTUSS Trial.
J Rheumatol., (2016), 43 pp. 1672-1679
[54]
J.J. Solomon , S.K. Danoff, H.J. Goldberg, F. Woodhead, M. Kolb, D.C. Chambers, et al.
Trail Network. The design and rationale of the Trail1 trial: A randomized double-blind phase 2 clinical trial of pirfenidone in rheumatoid arthritis-associated interstitial lung disease.
Adv Ther., (2019), 36 pp. 3279-3287
